CareDx (CDNA)
Healthcare · Medical - Diagnostics & Research
1 member of Congress has disclosed 1 trade in CareDx (CDNA) since 2023: 0 buys and 1 sale. The most recent was disclosed on Apr 17, 2023.
- Trades disclosed
- 1
- Members trading
- 1
- Buys / sells
- 0 / 1
- Reported value
- $1K–$15K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at CDNA
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
CDNA: second_quarter 2026 lobbying report
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Public: Oct 20, 2026, 4:36 PM EDTOriginal source ↗CDNA: third_quarter 2026 lobbying report
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) -Prior authorization of molecular tests Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Public: Oct 13, 2026, 3:56 PM EDTOriginal source ↗CDNA: second_quarter 2026 lobbying report
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Public: Jul 20, 2026, 7:30 PM EDTOriginal source ↗CDNA: second_quarter 2026 lobbying report
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) -Prior authorization of molecular tests Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Public: Jul 20, 2026, 1:53 PM EDTOriginal source ↗
Who traded CDNA
- Rep. Daniel S. Goldman (D-NY-10)0 buys · 1 sale01Apr 17, 2023
All trades
- Apr 17, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.